The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: US Stocks Seen Lower On Earnings, Ahead Of Data

Wed, 30th Apr 2014 12:04

LONDON (Alliance News) - US equities are set to open marginally lower Wednesday, as investors digest the latest tranche of quarterly trading statements released after the Wall Street close on Tuesday, and ahead of some important US macroeconomic data and the latest Federal Open Market Committee policy meeting decisions.

"US markets look set to open lower Wednesday as earnings from Twitter and eBay after the close yesterday pointed to lower-than-expected future growth," says Jasper Lawler, market analyst at CMC Markets.

Online retailer eBay posted a net loss of USD2.3 billion, or USD1.82 per share, in the first quarter, compared with net income of USD677 million in the same quarter last year. Although its quarterly earnings per share, excluding items, as well as quarterly revenue came in above analysts' expectations, the company's second-quarter guidance was weak.

Meanwhile, Twitter posted a net loss of USD132 million, or USD23 cents per share, in the first quarter, compared to a net loss of USD27 million in the same period last year. The company also issued 2014 revenue guidance that was lukewarm.

Twitter is down 13% in pre-market trading, while eBay is down 4.3%.

"Also playing into today's cautious approach from investors is likely to be the amount of important data releases lined up, not to mention the FOMC decision later on," says Craig Erlam, market analyst at Alpari.

"We've just come off two very good days, it is only logical to lock in some profits when there is GDP and ADP employment data and a central bank decision to come," he adds.

Ahead of the New York bell, the NASDAQ Composite is called to open down 0.3%, while the DJIA and S&P 500 are indicated to open marginally lower.

ADP employment change is released at 1215 GMT. Economists' expectations are for the reading, which is often regarded as indicative of the highly anticipated non-farm payrolls data released later in the week, to show that the private sector to have added 210,000 jobs compared to the 191,000 jobs added in March.

The preliminary reading of US first quarter GDP is published at 1230 GMT. This is "widely expected to be disappointing after the deep-freeze US winter," said Michael Hewson, chief market analyst at CMC Markets. An annualised reading of 1.2% is expected, down from 2.6% in the fourth quarter of last year.

The Chicago purchasing managers' index is released at 1345 GMT.

Later in the day, the US Federal Open Market Committee publishes its latest interest rate and monetary policy decisions at 1800 GMT.

In the UK, stocks continue to trade mixed. The FTSE 100 is up 0.2% at 6,786.08, the FTSE 250 is down 0.5% at 15,820.14, and the AIM All-Share index is up 0.8% at 822.28.

At the individual stock level, GlaxoSmithKline has just released its results for the first quarter of 2014. The drugs giant reported a drop in revenue and net profit for the quarter due to asset sales and a decline in sales of pharmaceuticals in the US, but the company also raised its dividend and reiterated its full-year profit guidance despite making its sales guidance more vague.

Its net profit fell to GBP668 million in the three months to end-March from GBP961 million a year earlier, as revenue declined to GBP5.61 billion from GBP6.47 billion. That was mainly due to asset sales and masked lower costs that resulted from its restructuring programme.

The company is is currently one of the biggest fallers in the blue-chip index, down 1.4%.

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.